[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
Jens Spahn noted on ZDF’s German national public service television news service on Monday night that the Brussels board had only reached a preliminary agreement with vaccine development companies to buy the product.
Commission President Ursula von der Leyen wrote in a Twitter post on Monday that a treaty will soon be signed that would allow the EU to obtain up to 300 million doses of the vaccine. important. Therefore, the Berlin management is putting very, very strong pressure on the committee to finalize the transport framework contract as soon as possible.
As German Health Minister, it would be difficult for me to explain how a vaccine made in Germany can be introduced earlier in other parts of the world than at home.
said the politician.
He stressed that the vaccine called BNT162b2 was very effective based on preliminary results of independent official tests. Seasonal influenza vaccines generally protect 50 to 60 percent of those vaccinated against infection, while the effectiveness of the SARS-Cov-2 vaccine from Pfizer and BioNTech is greater than 90 percent, based on experimental results. preliminaries.
However, the data is not definitive because testing for the substance is not yet complete. However, the results are still very encouraging, as “at least as it is today” means that “we are now obtaining the fastest vaccine against a new virus in human history.”
I am somewhat proud that a German company supported by us (the federal government) is so at the forefront of the investigation.
Said Jens Spahn.
Pfizer and BioNTech announced Monday that they have achieved efficiencies of more than 90 percent based on data collected in the final third phase of vaccine testing. As they wrote, they will continue to work and hope to have enough data by the third week of November to activate the Emergency Use Authorization (USA) from the Food and Drug Administration (FDA).
According to them, they can produce approximately fifty million batches of BNT162b2 this year and 1.3 billion next. The result of the development is the victory of innovation, science and global collaboration, he quoted Ugur Sahin, co-founder and CEO of Turkish-born BioNtech, who came to Germany as an immigrant.
Originally specialized in cancer treatment, BioNtech in Mainz and New York-based Pfizer Lightspeed began their development program in the first weeks of the pandemic. The German Federal Vaccine Authority, the Paul Ehrlich Institute (Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel – PEI), granted permission for human testing of the vaccine in April. Clinical trials began in the United States in May.
BNT162b2 may be the first SARS-Cov-2 vaccine approved by drug regulatory authorities in the Western world. The developers have so far signed a supply contract with the British and American governments.
Cover Image Source: Jakub Porzycki / NurPhoto via Getty Images
[ad_2]
